Cardax Inc
OTC:CDXI

Watchlist Manager
Cardax Inc Logo
Cardax Inc
OTC:CDXI
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 80.3 USD

Operating Margin

-584.8%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-584.8%
=
Operating Income
$-2.9m
/
Revenue
$500.7k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-584.8%
=
Operating Income
$-2.9m
/
Revenue
$500.7k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Cardax Inc
OTC:CDXI
80.3 USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-584.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Cardax Inc
Glance View

Market Cap
80.3 USD
Industry
Pharmaceuticals

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.

CDXI Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-584.8%
=
Operating Income
$-2.9m
/
Revenue
$500.7k
How has Operating Margin changed over time?

Over the last 1 years, Cardax Inc’s Operating Margin has decreased from -573.4% to -584.8%. During this period, it reached a low of -584.8% on May 1, 2021 and a high of -463.9% on Jun 30, 2020.

Back to Top